SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

26 Oct 2022 Evaluate
The revenue for the September 2022 quarter is pegged at Rs. 10483.09 millions against Rs. 10804.69 millions recorded during the year-ago period.The Company's Net profit for the September 2022 quarter have declined marginally to Rs. 2396.30  millions as against Rs. 3021.20 millions reported during the corresponding quarter ended.A decline of 3608.59 millions was observed in the OP in the quarter ended September 2022 from 4278.38 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 10483.09 10804.69 -2.98 19052.07 22343.69 -14.73 44007.08 34628.76 27.08
Other Income 656.24 511.97 28.18 1400.16 1130.37 23.87 2239.40 1347.76 66.16
PBIDT 3608.59 4278.38 -15.66 7054.54 9259.79 -23.82 17345.79 14370.43 20.70
Interest 17.17 10.24 67.68 26.17 20.25 29.23 52.40 34.11 53.62
PBDT 3591.42 4268.14 -15.86 7028.37 9239.54 -23.93 17293.39 14336.32 20.63
Depreciation 366.72 261.10 40.45 715.83 513.87 39.30 1102.96 987.80 11.66
PBT 3224.70 4007.04 -19.52 6312.54 8725.67 -27.66 16190.43 13348.52 21.29
TAX 828.40 985.84 -15.97 1621.70 2197.72 -26.21 4068.88 3378.47 20.44
Deferred Tax 21.89 56.89 -61.52 60.79 41.83 45.33 140.08 1.20 11573.33
PAT 2396.30 3021.20 -20.68 4690.84 6527.95 -28.14 12121.55 9970.05 21.58
Equity 164.69 164.23 0.28 164.69 164.23 0.28 164.30 163.59 0.43
PBIDTM(%) 34.42 39.60 -13.07 37.03 41.44 -10.65 39.42 41.50 -5.02

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×